Reslizumab, CAS 241473-69-8

Product Description: Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298./[2]Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4./[3]Egan RW, Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999 Sep;49(9):779-90.

CAS Number: 241473-69-8

Molecular Weight: N/A

Compound Purity: 99.40

Research Area: Inflammation/Immunology

Solubility: H2O

Target: Interleukin Related

• Artikelnummer: MEXHY-P9949-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9949-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated